+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Primary Immune Deficiency (PID) - Pipeline Review, H1 2019

  • ID: 4760841
  • Drug Pipelines
  • 104 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • ADMA Biologics Inc
  • Biotest AG
  • GC Pharma
  • GigaGen Inc
  • Novartis AG
  • Octapharma AG
  • MORE
Primary Immune Deficiency (PID) - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2019, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights

This latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 8, 3, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 8, 1 and 5 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ADMA Biologics Inc
  • Biotest AG
  • GC Pharma
  • GigaGen Inc
  • Novartis AG
  • Octapharma AG
  • MORE
Introduction

Primary Immune Deficiency (PID) - Overview

Primary Immune Deficiency (PID) - Therapeutics Development

Primary Immune Deficiency (PID) - Therapeutics Assessment

Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development

Primary Immune Deficiency (PID) - Drug Profiles

Primary Immune Deficiency (PID) - Dormant Projects

Primary Immune Deficiency (PID) - Discontinued Products

Primary Immune Deficiency (PID) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Primary Immune Deficiency (PID), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H1 2019

Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H1 2019

Primary Immune Deficiency (PID) - Pipeline by GC Pharma, H1 2019

Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H1 2019

Primary Immune Deficiency (PID) - Pipeline by Novartis AG, H1 2019

Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H1 2019

Primary Immune Deficiency (PID) - Pipeline by Orchard Therapeutics Plc, H1 2019

Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc, H1 2019

Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H1 2019

Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H1 2019

Primary Immune Deficiency (PID) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H1 2019

Primary Immune Deficiency (PID) - Dormant Projects, H1 2019

Primary Immune Deficiency (PID) - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Primary Immune Deficiency (PID), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ADMA Biologics Inc
  • Biotest AG
  • GC Pharma
  • GigaGen Inc
  • Novartis AG
  • Octapharma AG
  • Orchard Therapeutics Plc
  • ProMetic Life Sciences Inc
  • Sangamo Therapeutics Inc
  • Taiga Biotechnologies Inc
  • Takeda Pharmaceutical Co Ltd
  • X4 Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760841
Adroll
adroll